Global Secondary Progressive Multiple Sclerosis Drug Market Data Survey Report 2025
Table of Contents
1 Global Market Overview
- 1.1 Scope of Statistics
- 1.1.1 Scope of Products
- 1.1.2 Scope of Manufacturers
- 1.1.3 Scope of Application
- 1.1.5 Scope of Regions/Countries
- 1.2 Global Market Size
2 Regional Market
- 2.1 Regional Production
- 2.2 Regional Demand
- 2.3 Regional Trade
3 Key Manufacturers
- 3.1 AB Science SA
- 3.1.2 Company Information
- 3.1.2 Product Specifications
- 3.1.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
- 3.2 Actelion Ltd
- 3.2.1 Company Information
- 3.2.2 Product Specifications
- 3.2.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
- 3.3 Biogen, Inc.
- 3.3.1 Company Information
- 3.3.2 Product Specifications
- 3.3.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
- 3.4 F. Hoffmann-La Roche Ltd.
- 3.4.1 Company Information
- 3.4.2 Product Specifications
- 3.4.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
- 3.5 Genzyme Corporation
- 3.5.1 Company Information
- 3.5.2 Product Specifications
- 3.5.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
- 3.6 Glialogix, Inc.
- 3.6.1 Company Information
- 3.6.2 Product Specifications
- 3.6.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
- 3.7 Glialogix, Inc.
- 3.7.1 Company Information
- 3.7.2 Product Specifications
- 3.7.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
- 3.8 Innate Immunotherapeutics Ltd
- 3.8.1 Company Information
- 3.8.2 Product Specifications
- 3.8.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
- 3.9 Kyorin Pharmaceutical Co., Ltd.
- 3.9.1 Company Information
- 3.9.2 Product Specifications
- 3.9.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
- 3.10 Mallinckrodt Plc
- 3.10.1 Company Information
- 3.10.2 Product Specifications
- 3.10.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
- 3.11 MedDay SA
- 3.12 MedImmune, LLC
- 3.13 Merck KGaA
- 3.14 Meta-IQ ApS
- 3.15 Novartis AG
- 3.16 Opexa Therapeutics, Inc.
- 3.17 Xenetic Biosciences (UK) Limited
4 Major Application
- 4.1 Hospital
- 4.1.1 Overview
- 4.1.2 Hospital Market Size and Forecast
- 4.2 Clinic
- 4.2.1 Overview
- 4.2.2 Clinic Market Size and Forecast
- 4.3 Others
- 4.3.1 Overview
- 4.3.2 Others Market Size and Forecast
5 Market by Type
- 5.1 Inebilizumab
- 5.1.1 Overview
- 5.1.2 Inebilizumab Market Size and Forecast
- 5.2 GLX-1112
- 5.2.1 Overview
- 5.2.2 GLX-1112 Market Size and Forecast
- 5.3 DC-TAB
- 5.3.1 Overview
- 5.3.2 DC-TAB Market Size and Forecast
- 5.4 Etomoxir
- 5.4.1 Overview
- 5.4.2 Etomoxir Market Size and Forecast
- 5.5 IB-MS
- 5.5.1 Overview
- 5.5.2 IB-MS Market Size and Forecast
- 5.6 IB-MS
- 5.6.1 Overview
- 5.6.2 IB-MS Market Size and Forecast
6 Conclusion
Summary
The global Secondary Progressive Multiple Sclerosis Drug market will reach Volume Million USD in 2018 with CAGR xx% 2018-2025. The main contents of the report including:
Global market size and forecast
Regional market size, production data and export & import
Key manufacturers (manufacturing sites, capacity and production, product specifications etc.)
Major Application
Major Type
Key manufacturers are included based on manufacturing sites, capacity and production, product specifications etc.:
AB Science SA
Actelion Ltd
Biogen, Inc.
F. Hoffmann-La Roche Ltd.
Genzyme Corporation
Glialogix, Inc.
Glialogix, Inc.
Innate Immunotherapeutics Ltd
Kyorin Pharmaceutical Co., Ltd.
Mallinckrodt Plc
MedDay SA
MedImmune, LLC
Merck KGaA
Meta-IQ ApS
Novartis AG
Opexa Therapeutics, Inc.
Xenetic Biosciences (UK) Limited
Major applications as follows:
Hospital
Clinic
Others
Major Type as follows:
Inebilizumab
GLX-1112
DC-TAB
Etomoxir
IB-MS
Others
Regional market size, production data and export & import:
Asia-Pacific
North America
Europe
South America
Middle East & Africa